Fondamentali CPHL
CITI PHARMA LIMITED bilanci, compresi i ricavi, spese e i profitti
Il fatturato totale di CPHL per l'ultimo trimestre è di 3.53 B PKR, in crescita del 9.61% rispetto al trimestre precedente. L'utile netto nel Q2 25 è di 256.98 M PKR.
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
0,00
900,00 M
1,80 B
2,70 B
3,60 B
Fatturato totale
Utile lordo
Utile operativo
Utile lordo
Utile netto
Valuta: PKR
Q1 '21
Set 2020
Q2 '21
Dic 2020
Q3 '21
Mar 2021
Q4 '21
Giu 2021
Q1 '22
Set 2021
Q2 '22
Dic 2021
Q3 '22
Mar 2022
Q4 '22
Giu 2022
Q1 '23
Set 2022
Q2 '23
Dic 2022
Q3 '23
Mar 2023
Q4 '23
Giu 2023
Q1 '24
Set 2023
Q2 '24
Dic 2023
Q3 '24
Mar 2024
Q4 '24
Giu 2024
Q1 '25
Set 2024
Q2 '25
Dic 2024
TTM
Fatturato totaleCrescita YoY
2,69 B
−2,16%
3,54 B
+61,49%
2,70 B
−13,37%
3,28 B
+7,28%
3,56 B
+32,36%
2,87 B
−18,75%
3,22 B
+19,38%
3,53 B
+7,92%
13,19 B
−2,34 B
−3,30 B
−2,45 B
−2,65 B
−3,09 B
−2,63 B
−2,80 B
−3,00 B
−11,51 B
Utile lordoCrescita YoY
350,42 M
−0,83%
241,27 M
−18,86%
246,47 M
−33,46%
625,17 M
+14,70%
471,53 M
+34,56%
243,03 M
+0,73%
428,51 M
+73,86%
539,13 M
−13,76%
1,68 B
−62,06 M
−105,50 M
−86,90 M
−82,76 M
−85,60 M
−125,30 M
−87,10 M
−101,38 M
−399,37 M
Utile operativoCrescita YoY
288,35 M
−7,53%
135,77 M
−40,28%
159,57 M
−43,62%
542,41 M
+17,83%
385,93 M
+33,84%
117,73 M
−13,28%
341,42 M
+113,96%
437,75 M
−19,29%
1,28 B
−149,17 M
50,39 M
7,05 M
44,09 M
−21,06 M
45,47 M
−1,12 M
−43,58 M
−20,28 M
Utile lordoCrescita YoY
139,18 M
−55,84%
186,16 M
−26,34%
166,63 M
−1,60%
586,50 M
+26,79%
364,87 M
+162,16%
159,91 M
−14,10%
340,29 M
+104,23%
394,17 M
−32,79%
1,26 B
−46,42 M
−61,57 M
−72,17 M
−210,90 M
−153,53 M
−7,84 M
−138,80 M
−137,20 M
−437,36 M
92,77 M
124,58 M
94,45 M
375,60 M
211,35 M
152,07 M
201,50 M
256,98 M
821,89 M
Utile nettoCrescita YoY
92,77 M
−55,28%
124,58 M
+46,23%
94,45 M
−35,22%
375,60 M
+27,40%
211,35 M
+127,83%
152,07 M
+22,06%
201,50 M
+113,33%
256,98 M
−31,58%
821,89 M
92,77 M
124,58 M
94,45 M
375,60 M
211,35 M
152,07 M
201,50 M
256,98 M
821,89 M
Utile per azione, base (EPS base)Crescita YoY
0,41
−55,29%
0,55
+46,23%
0,41
−35,22%
1,64
+27,39%
0,93
+127,86%
0,67
+22,06%
0,88
+113,35%
1,12
−31,58%
3,60
Utile per azione, diluito (EPS diluito)Crescita YoY
0,41
−55,29%
0,55
+46,23%
0,41
−35,22%
1,64
+27,39%
0,93
+127,86%
0,67
+22,06%
0,88
+113,35%
1,12
−31,58%
3,60
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
—
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
228,46 M
—
EBITDACrescita YoY
316,10 M
−3,77%
155,04 M
−37,69%
190,76 M
−37,38%
560,32 M
+16,18%
429,27 M
+35,80%
163,51 M
+5,47%
382,50 M
+100,52%
459,32 M
−18,03%
1,43 B
EBITCrescita YoY
288,35 M
−7,53%
135,77 M
−40,28%
159,57 M
−43,62%
542,41 M
+17,83%
385,93 M
+33,84%
117,73 M
−13,28%
341,42 M
+113,96%
437,75 M
−19,29%
1,28 B
−2,40 B
−3,40 B
−2,54 B
−2,73 B
−3,17 B
−2,76 B
−2,88 B
−3,10 B
−11,91 B